Emisphere Technologies, Inc. Release: Study Results Add to Evidence of Effectiveness of Oral Calcitonin Using Eligen(r) Technology in Suppression of Bone Resorption

CEDAR KNOLLS, N.J., Feb. 20, 2009 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (Nasdaq:EMIS) announced results of a study indicating that orally administered salmon calcitonin using Emisphere’s carrier, (5-CNAC) an Eligen(r) oral delivery technology, is effective in reducing bone breakdown. The study was conducted on behalf of Emisphere’s partner Novartis Pharma AG by Nordic Bioscience, and published in BMC Clinical Pharmacology.